Prognosis
Mpox Gives Denmark Yet Another Way to Flex Its Pharma Power
- Tiny Nordic nation is outshining US and UK for in-demand drugs
- Denmark’s emergence fueled by long-term investment strategies
This article is for subscribers only.
After the World Health Organization this week warned that a fast-spreading strain of mpox poses a global threat, Denmark again has a potential solution and underscored its capacity to outshine traditional powerhouses in the US and the UK.
From treatments for diabetes to depression, the Nordic nation of 6 million people has punched above its weight with its prowess in pharmaceuticals, and Bavarian Nordic A/S’s mpox vaccine — the only regulator-approved inoculation for the deadly virus — serves as the latest milestone.